In support of this concept, treatment with DNMT inhibitor 5-azacitidine led to the substantial enrichment for immunomodulatory pathways (interferon signaling, antigen processing and presentation, and cytokines/chemokines) in ovarian and other cancers [241]. This evidence concerns the gene DNMT1 and cancer.